Bladder Cancer
Also known as: Adenoma, Adenomatous, Tumor, Neoplasm
Methodology & AI Transparency ⓘ
Bladder Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The bladder is a hollow organ in your lower abdomen that stores urine.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C67.9 for Bladder Cancer clinical workups.
- 3 Typical cash cost range: Differential triage of Bladder Cancer (C67.9) utilizes multidisciplinary tumor-board planning in Bladder Cancer (C67.9: (surgery).
- 4 Top reported side effects / signs: Follow-up benchmark in Bladder Cancer: maintaining Comprehensive Metabolic & in Bladder Cancer (C67.9: Organ Function Panel) within Preserved renal/hepatic clearance (C67.9).
Ask our AI Specialists anything about Bladder Cancer
What Is Bladder Cancer?
The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include: Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, White, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Bladder Cancer (C67.9) features immune-checkpoint evasion [Bladder Cancer C67.9]. Cross-referenced with NIH MeSH (Urinary Bladder Neoplasms), therapeutic stabilization in cancer & oncology is verified against Pathology / Molecular in Bladder Cancer (C67.9: Genomic Staging).
Common Symptoms & Clinical Signs
- • Blood in your urine
- • A frequent urge to urinate
- • Presentation of Bladder Cancer (C67.9): unintended weight loss [Bladder Cancer C67.9]
- • Secondary Bladder Cancer clinical sign: unexplained bleeding, chronic in Bladder Cancer (C67.9: hoarseness/cough, or progressive)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Bladder Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C67.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Bladder Cancer (C67.9: Organ Function Panel) | Preserved renal/hepatic clearance (C67.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Bladder Cancer (C67.9: Genomic Staging) | Guideline-concordant surveillance (C67.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Bladder Cancer (C67.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C67.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bladder Cancer
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Tolterodine Tartrate Detrol • RxCUI 855178 | Cholinergic Muscarinic Antagonist | 80% | $0.2000 | $ 7.10 /mo |
| Solifenacin Succiate Solifenacin Succinate • RxCUI 477372 | Cholinergic Muscarinic Antagonist | 80% | $0.1816 | $ 15.85 /mo |
| Mirabegron Mirabgeorn, Myrbetriq • RxCUI 1300791 | beta3-Adrenergic Agonist | 84% | $9.0229 | $ 185.00 /mo |
| Hexaminolevulinate Hydrochloride Cysview • RxCUI RXN-105113001-1757 | FDA Prescription Therapeutic Agent | 88% | $1.0700 | $ 51.84 /mo |
| Fesoterodine Fumarate Toviaz • RxCUI 810071 | FDA Prescription Therapeutic Agent | 89% | $0.7765 | $ 39.95 /mo |
| Trospium Chloride Sanctura • RxCUI 857560 | Cholinergic Muscarinic Antagonist | 77% | $0.2068 | $ 9.51 /mo |
| Vibegron Gemtesa • RxCUI 2472315 | beta3-Adrenergic Agonist | 74% | $15.9926 | $ 185.00 /mo |
| Oxybutynin Oxytrol for Women, Oxytrol • RxCUI 863619 | Cholinergic Muscarinic Antagonist | 79% | $0.0817 | $ 6.05 /mo |
| Darifenacin Hydrobromide Darifenacin Hydrobromide Generic • RxCUI 485421 | Cholinergic Muscarinic Antagonist | 80% | $0.5494 | $ 30.75 /mo |
| Oxybutynin Chloride Ditropan • RxCUI 863664 | Cholinergic Muscarinic Antagonist | 78% | $0.0455 | $ 5.98 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bladder Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder: What a 538-Participant Study Found In this post hoc responder analysis from the phase 3 COURAGE trial, participants receiving vibegron vs placebo achieved clinically relevant reductions in bothersome OAB symptoms, as well as improvements in IPSS and OAB-q scores. Urology • 2025-12-15 • Phase III Randomized Trial | N = 538 | 93/100 | PMID 40902908 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Olanzapine in Children Receiving Highly Emetogenic Olanzapine significantly improved complete control of vomiting in the delayed phase. Journal of pediatric hematology/oncology • 2022-11-01 • Phase III Randomized Trial | N = 128 | 88/100 | PMID 35091522 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients PFS for the Taiwanese participants of RELAY receiving RAM+ERL versus ERL+PBO was consistent with that in the overall RELAY population. Targeted oncology • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37329423 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical Performance of Tissue- and Plasma-Based Diagnostic Assays in Identifying Clinically meaningful benefits for all end points were comparable for BRCA + and HRR + patients detected by. The Journal of molecular diagnostics : JMD • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41167302 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of skin-adhesive low-level light therapy for overactive LLLT may be clinically useful and safe for the treatment of OAB. International urogynecology journal • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35389054 ↗ |
Bladder Cancer Patient Community & “People Like Me” Threads
Filter Bladder Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.